Table 2 Clinical data of PCa patients analyzed by IHC using TMA with regard to TET1 expression (n = 371 patients in total)
Count (%) | Age (y) | PSA (ng/mL) | |||
|---|---|---|---|---|---|
Median | Range | Median | Range | ||
Low risk | 97 (26.2%) | 64.6 | 48.5–78.3 | 5.74 | 0.2–38.4 |
Intermed. risk | 45 (12.1%) | 64.9 | 50.6–76.9 | 12.9 | 2.9–83.8 |
High risk | 229 (61.7%) | 65.5 | 46.7–77.4 | 9.9 | 0.3–113 |
T2a–c | 165 (44.5%) | 65.1 | 46.7–78.3 | 7.2 | 0.2–45.1 |
T3a-b | 144 (38.8%) | 65.9 | 54.1–77.4 | 8.7 | 0.3–74.8 |
T4 | 62 (16.7%) | 63.2 | 50.6–76.5 | 15.8 | 2.8–113 |
GS ≤ 6 | 73 (19.7%) | 64.3 | 48.5–77.1 | 5.6 | 0.2–83.8 |
GS7 | 69 (18.6%) | 65.6 | 50.6–78.3 | 8.0 | 2.9–50 |
GS8 | 147 (39.6%) | 66.1 | 46.7–77.4 | 10.5 | 0.3–113 |
GS ≥ 9 | 82 (22.1%) | 64.6 | 51.1–77.1 | 8.8 | 0.3–65.5 |